Two years before the release of Nosferatu, Robert Eggers directed the epic action drama film The Northman. After an underwhelming theatrical run, the film is now enjoying newfound global success on ...

Viking Therapeutics has reported phase 2 data on its oral obesity drug candidate, linking the peptide to weight loss of up to 12.2% after 13 weeks. But, with 38% of patients discontinuing treatment at ...

The safety and tolerability data were at odds with an earlier phase 1 trial, and not as good as a comparable drug trial result from Eli Lilly. Viking may decide to take VK2735 (oral form) through ...

(Reuters) - Viking Therapeutics said on Tuesday its experimental weight-loss pill helped people with obesity lose up to 12.2% of their body weight over 13 weeks in a keenly watched study. Yet, shares ...

Disappointing tolerability results accompanied impressive body weight loss data. It's a setback, but Viking Therapeutics still has strategic options. The trial may have contained a tough sample group.

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Alexander Skarsgård's breathtaking Viking-inspired film, The Northman, has arrived on Netflix in the UK and Ireland – and safe to say, its one that needs to be added to your watchlist. Directed by ...

Aug 19 (Reuters) - Viking Therapeutics (VKTX.O), opens new tab said Tuesday its experimental weight-loss pill helped patients lose 12.2% of their body weight in a mid-stage trial, missing Wall ...

Viking stock dropped after Phase 2 obesity pill data showed higher discontinuations. William Blair kept an Outperform rating, calling the sell-off excessive. Get Discounted Real-Time Trade Alerts For ...

Revenue: Increased 18.5% year over year to $1.9 billion. Net Yield: Increased 8% to $607. Capacity Growth: Increased 8.8% this quarter. Adjusted Gross Margin: Increased 19.2% year over year to $1.2 ...

Led by strength in its Ocean voyages, Viking Holdings (NYSE:VIK) realized a 19% increase in revenue during the second quarter, driving the company’s adjusted profits up 24% per share. Shares are under ...

Notes: 1) Safety population, includes all randomized subjects who received at least one dose of study drug. 2) Patients treated with VK2735 were titrated to final doses as indicated: 15 mg cohort = 15 ...